Investing.com -- Merck & Co (NYSE:MRK), the New Jersey-based pharmaceutical giant, has announced a halt in shipments of its ...

The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is halting shipments to the world’s second-most populous country.

Merck said on Tuesday it would not ship its HPV vaccine Gardasil in China until at least the middle of this year due to weak discretionary spending, a move that dented its full-year forecast and ...

Merck & Co.’s blockbuster vaccine Gardasil has had a roller-coaster ride in China. A post-Covid surge in demand for the cancer-preventing shot quickly deflated last year, to the point the US ...

A federal judge ruled in Merck & Co.’s favor in a safety lawsuit over its Gardasil vaccine, allowing the drugmaker to ...

On Thursday, Merck & Co Inc (NYSE:MRK) reported third-quarter sales of $16.66 billion, up 4% year over year, beating the consensus of $16.47 billion. Merck reported a decline of 11% in sales of ...

In a significant blow to plaintiffs suing over the HPV vaccine Gardasil, a federal judge on Tuesday sided with Merck & Co. Inc. on its implied preemption defense.

Goldman Sachs discusses Gardasil's performance in China with Merck's Joe Romanelli. Gardasil faces challenges due to market issues and partner Zhifei's operational problems, impacting Q2 sales.

Pharma giant Merck and Co., hopes to offer Gardasil, to developing countries at affordable rates. Gardasil, marketed by Merck is the only vaccine against Human Papilloma Virus, that is insinuated ...

Drugmaker Merck & Co Inc on Thursday posted better-than-expected results for the first quarter on the strength of its blockbuster cancer immunotherapy Keytruda and human papillomavirus (HPV ...

A federal judge ruled in Merck & Co.’s favor in a safety lawsuit over its Gardasil vaccine, allowing the drugmaker to sidestep more than 200 cases claiming the company concealed safety risks.

Keytruda sales surged 17% YoY to $7.43B, while Gardasil sales dropped 11% to $2.31B due to reduced demand in China. Merck's Q3 sales reached $16.7 billion, a 4% YoY increase, beating the $16.5 ...